Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pseudo-hypoaldosteronisms].

Marie-Christine Vantyghem1, Pierrette Perimenis, Jean-Louis Wemeau

  • 1Service d'endocrinologie et métabolisme, Centre hospitalo-universitaire de Lille (59). mc.vantyghem@chru-lille.fr

Presse Medicale (Paris, France : 1983)
|March 18, 2004
PubMed
Summary

Pseudohypoaldosteronism presents in two forms: Type 1 with hypotension and Type 2 with hypertension. Both involve aldosterone resistance, leading to hyperkalemia and hyperaldosteronism, with distinct genetic causes and clinical features.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cindynics is de rigueur in laboratories and hospital units<sup>✰</sup>.

Presse medicale (Paris, France : 1983)·2026
Same author

Maturity Onset Diabetes of the Young (MODY): French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins).

Orphanet journal of rare diseases·2026
Same author

Bone phenotype in familial partial lipodystrophy type 2: Insulin resistance and sclerostin.

Diabetes & metabolism·2026
Same author

Risk of bone overstimulation in long-term PTH(1-34) therapy for hypoparathyroidism.

European journal of endocrinology·2026
Same author

<i>NKX6.1</i> mRNA copy number is an actionable biomarker associated with islet function and clinical outcomes after islet transplantation.

Science translational medicine·2026
Same author

Laminopathies: natural history and risk prediction of heart failure.

European heart journal·2026

Area of Science:

  • Endocrinology
  • Nephrology
  • Genetics

Context:

  • Pseudohypoaldosteronism (PHA) encompasses conditions of end-organ resistance to aldosterone.
  • PHA is classified into two main types based on blood pressure: Type 1 (hypotension) and Type 2 (hypertension).

Purpose:

  • To differentiate the two forms of pseudohypoaldosteronism based on clinical presentation and underlying genetic mechanisms.
  • To elucidate the genetic basis and clinical manifestations of PHA Type 1 and Type 2.

Summary:

  • Type 1 PHA is associated with hypotension, high renin, and type 4 tubular acidosis, stemming from excessive salt loss (urinary or digestive) or genetic mutations (mineralocorticoid receptor, amiloride-sensitive sodium channel).
  • Type 2 PHA, or Gordon's syndrome, presents with hypertension, hyperkalemia, and hyperaldosteronism, linked to mutations in WNK genes, affecting ion transport and blood pressure regulation.

Impact:

  • Understanding the distinct genetic and clinical profiles of PHA types aids in accurate diagnosis and management.
  • Identification of WNK kinases in PHA Type 2 highlights novel pathways regulating blood pressure and electrolyte balance.

Related Experiment Videos